Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (12 quarters reported)
$126M in Q4 2017 → $54.3M now. Hover for any quarter.
As reported for the quarter ended September 30, 2020. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| MS Myovant Sciences Ltd. | 90.0% | Unchanged | 3,474,645 | $48.8M |
| RT Revance Therapeutics, Inc. | 10.0% | Trimmed 64% | 216,038 | $5.43M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2020 · filed November 13, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| RT Revance Therapeutics, Inc. | Trimmed | −382,947 | −$9.63M | 10.0% |
quarter ended June 30, 2020 · filed July 24, 2020
No position changes this quarter.
quarter ended March 31, 2020 · filed April 24, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| RT Revance Therapeutics, Inc. | Trimmed | −959,441 | −$14.2M | 25.3% |
quarter ended December 31, 2019 · filed January 24, 2020
No position changes this quarter.
quarter ended September 30, 2019 · filed October 25, 2019
No position changes this quarter.
quarter ended June 30, 2019 · filed July 29, 2019
No position changes this quarter.
quarter ended March 31, 2019 · filed May 08, 2019
No position changes this quarter.
quarter ended December 31, 2018 · filed February 12, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| MS Myovant Sciences Ltd. | Added | +2,286,284 | +$37.5M | 64.5% |
Loading...
